FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137661559> ?p ?o ?g. }

• W3137661559 abstract "Abstract Introduction A significant proportion of patients with Coronavirus Disease-19 (COVID-19) have hypertension and are treated with renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme I inhibitors (ACE inhibitors) or angiotensin II type-1 receptor blockers (ARBs). These medications have been postulated to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The objective of this study was to assess a possible association between prescription of RAS inhibitors and the incidence of COVID-19 and all-cause mortality. Methods We conducted a propensity-score matched cohort study to assess the incidence of COVID-19 among patients with hypertension who were prescribed ACE inhibitors or ARBs compared to patients treated with calcium channel blockers (CCBs) in a large UK-based primary care database (The Health Improvement Network). We estimated crude incidence rates for confirmed/suspected COVID-19 among those prescribed ACE inhibitors, ARBs and CCBs. We used a Cox proportional hazards model to produce adjusted hazard ratios for COVID-19 comparing patients prescribed ACE inhibitors or ARBs to those prescribed CCBs. We further assessed all-cause mortality as a secondary outcome and a composite of accidents, trauma or fractures as a negative control outcome to assess for residual confounding. Results In the propensity score matched analysis, 83 of 18,895 users (0.44%) of ACE inhibitors developed COVID-19 over 8,923 person-years, an incidence rate of 9.3 per 1000 person-years. 85 of 18,895 (0.45%) users of CCBs developed COVID-19 over 8,932 person-years, an incidence rate of 9.5 per 1000 person-years. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ACE inhibitors compared to CCBs was 0.92 (95% CI 0.68 to 1.26). 79 out of 10,623 users (0.74%) of ARBs developed COVID-19 over 5010 person-years, an incidence rate of 15.8 per 1000 person-years, compared to 11.6 per 1000 person-years among users of CCBs. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ARBs compared to CCBs was 1.38 (95% CI 0.98 to 1.95). There were no significant associations between use of ACE inhibitors or ARBs and all-cause mortality, compared to use of CCBs. We found no evidence of significant residual confounding with the negative control analysis. Conclusion Current use of ACE inhibitors was not associated with the risk of suspected or confirmed COVID-19 whereas use of ARBs was associated with a statistically non-significant 38% relative increase in risk compared to use of CCBs. However, no significant associations were observed between prescription of either ACE inhibitors or ARBs and all-cause mortality during the peak of the pandemic." @default.
• W3137661559 created "2021-03-29" @default.
• W3137661559 creator A5004886844 @default.
• W3137661559 creator A5011124689 @default.
• W3137661559 creator A5011773057 @default.
• W3137661559 creator A5016610763 @default.
• W3137661559 creator A5022942437 @default.
• W3137661559 creator A5030382491 @default.
• W3137661559 creator A5031412055 @default.
• W3137661559 creator A5033859830 @default.
• W3137661559 creator A5039136529 @default.
• W3137661559 creator A5043836434 @default.
• W3137661559 creator A5046142260 @default.
• W3137661559 creator A5049122739 @default.
• W3137661559 creator A5057902494 @default.
• W3137661559 creator A5073989970 @default.
• W3137661559 creator A5075283925 @default.
• W3137661559 creator A5078630847 @default.
• W3137661559 creator A5082565570 @default.
• W3137661559 creator A5086156437 @default.
• W3137661559 creator A5087050868 @default.
• W3137661559 creator A5090110979 @default.
• W3137661559 date "2020-09-18" @default.
• W3137661559 modified "2023-09-23" @default.
• W3137661559 title "Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care" @default.
• W3137661559 cites W2083695720 @default.
• W3137661559 cites W2171671715 @default.
• W3137661559 cites W3007814559 @default.
• W3137661559 cites W3012771079 @default.
• W3137661559 cites W3013871850 @default.
• W3137661559 cites W3019849260 @default.
• W3137661559 cites W3021241497 @default.
• W3137661559 cites W3023614024 @default.
• W3137661559 cites W3023640683 @default.
• W3137661559 cites W3023702343 @default.
• W3137661559 cites W3035819488 @default.
• W3137661559 cites W4233755621 @default.
• W3137661559 doi "https://doi.org/10.1101/2020.09.17.20196469" @default.
• W3137661559 hasPublicationYear "2020" @default.
• W3137661559 type Work @default.
• W3137661559 sameAs 3137661559 @default.
• W3137661559 citedByCount "0" @default.
• W3137661559 crossrefType "posted-content" @default.
• W3137661559 hasAuthorship W3137661559A5004886844 @default.
• W3137661559 hasAuthorship W3137661559A5011124689 @default.
• W3137661559 hasAuthorship W3137661559A5011773057 @default.
• W3137661559 hasAuthorship W3137661559A5016610763 @default.
• W3137661559 hasAuthorship W3137661559A5022942437 @default.
• W3137661559 hasAuthorship W3137661559A5030382491 @default.
• W3137661559 hasAuthorship W3137661559A5031412055 @default.
• W3137661559 hasAuthorship W3137661559A5033859830 @default.
• W3137661559 hasAuthorship W3137661559A5039136529 @default.
• W3137661559 hasAuthorship W3137661559A5043836434 @default.
• W3137661559 hasAuthorship W3137661559A5046142260 @default.
• W3137661559 hasAuthorship W3137661559A5049122739 @default.
• W3137661559 hasAuthorship W3137661559A5057902494 @default.
• W3137661559 hasAuthorship W3137661559A5073989970 @default.
• W3137661559 hasAuthorship W3137661559A5075283925 @default.
• W3137661559 hasAuthorship W3137661559A5078630847 @default.
• W3137661559 hasAuthorship W3137661559A5082565570 @default.
• W3137661559 hasAuthorship W3137661559A5086156437 @default.
• W3137661559 hasAuthorship W3137661559A5087050868 @default.
• W3137661559 hasAuthorship W3137661559A5090110979 @default.
• W3137661559 hasBestOaLocation W31376615591 @default.
• W3137661559 hasConcept C120665830 @default.
• W3137661559 hasConcept C121332964 @default.
• W3137661559 hasConcept C126322002 @default.
• W3137661559 hasConcept C17923572 @default.
• W3137661559 hasConcept C201903717 @default.
• W3137661559 hasConcept C207103383 @default.
• W3137661559 hasConcept C44249647 @default.
• W3137661559 hasConcept C50382708 @default.
• W3137661559 hasConcept C61511704 @default.
• W3137661559 hasConcept C71924100 @default.
• W3137661559 hasConcept C72563966 @default.
• W3137661559 hasConcept C77350462 @default.
• W3137661559 hasConceptScore W3137661559C120665830 @default.
• W3137661559 hasConceptScore W3137661559C121332964 @default.
• W3137661559 hasConceptScore W3137661559C126322002 @default.
• W3137661559 hasConceptScore W3137661559C17923572 @default.
• W3137661559 hasConceptScore W3137661559C201903717 @default.
• W3137661559 hasConceptScore W3137661559C207103383 @default.
• W3137661559 hasConceptScore W3137661559C44249647 @default.
• W3137661559 hasConceptScore W3137661559C50382708 @default.
• W3137661559 hasConceptScore W3137661559C61511704 @default.
• W3137661559 hasConceptScore W3137661559C71924100 @default.
• W3137661559 hasConceptScore W3137661559C72563966 @default.
• W3137661559 hasConceptScore W3137661559C77350462 @default.
• W3137661559 hasLocation W31376615591 @default.
• W3137661559 hasLocation W31376615592 @default.
• W3137661559 hasLocation W31376615593 @default.
• W3137661559 hasLocation W31376615594 @default.
• W3137661559 hasOpenAccess W3137661559 @default.
• W3137661559 hasPrimaryLocation W31376615591 @default.
• W3137661559 hasRelatedWork W1995982834 @default.
• W3137661559 hasRelatedWork W2023556803 @default.
• W3137661559 hasRelatedWork W2557114555 @default.
• W3137661559 hasRelatedWork W2584343805 @default.
• W3137661559 hasRelatedWork W2919644205 @default.
• W3137661559 hasRelatedWork W2980864243 @default.

• next